Stocks avoid Centoxin bloodbath

Stocks avoid Centoxin bloodbath

Centoxin redux didn't seem to reverberate as much as it could have through the offerings market, despite early-in-the-week jitters that suspension of Centocor's sepsis trial could turn off the spigot.

A resentful mood percolated among companies and

Read the full 435 word article

How to gain access

Continue reading with a
two-week free trial.